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Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
MicroRNAs as Possible Molecular Pacemakers 
Emanuela Boštjančič and Damjan Glavač 
University of Ljubljana, Faculty of Medicine, Institute of Pathology,  
Department of Molecular Genetics,  
Slovenia 
1. Introduction  
MicroRNAs (miRNAs) are endogenously expressed, small (approx. 22 nucleotides long) 
non-coding RNA molecules that regulate gene expression at the post-transcriptional level. 
They are encoded in almost all organisms, from viruses to humans (Soifer et al., 2007). 
Bioinformatic studies of the genomes of multiple organisms suggest that this short length 
maximizes target-gene specificity and minimizes non-specific effects. Generally, by targeting 
the 3'-untranslated region (UTR) of mRNAs in a sequence specific manner, they influence 
the translation (protein synthesis repression) or stability of the transcripts (mRNA 
degradation) (Ying et al., 2008). The role of endogenously expressed miRNA (the first 
miRNA to be discovered was lin-4) in down-regulating gene expression was first described 
by Victor Ambros and his colleagues in 1993 for C. Elegans, although the term microRNA 
was only introduced in 2001 (Lagos-Quintana et al., 2001; Lau, et al., 2001; Lee et al., 2001; 
Ruvkun, 2001). In humans, approx. 1700 mature miRNA have been cloned and sequenced 
(miRBase v17.0 database, release April 2011, http://www.mirbase.org). It is estimated that 
there could be as many as thousands of miRNAs in humans, thought to regulate approx. 30 
% of genes within the human genome (Pillai et al., 2007).  
1.1 MicroRNA biology  
MicroRNAs are genome encoded, derived from the intergenic regions, exon sequences of 
non-coding transcription units or intronic sequences of either protein coding or non-coding 
transcription units. They are encoded as a single gene or gene clusters. It has been predicted 
that miRNAs constitute more than 3 % of human genes (Pillai, 2005). Intergenic miRNAs are 
transcribed as an independent transcription unit, as a monocistronic, bicistronic or 
polycistronic primary transcript (Bartel, 2004). Intronic miRNA are usually part of introns of 
pre-mRNA, preferentially transcribed in the same orientation as the mRNA, probably not 
transcribed from their own promoters but instead processed from introns, as are many 
snoRNA. Intronic miRNAs and their host transcripts are co-regulated and co-transcribed 
from the same promoter (Kim & Kim, 2007). Within the genome, there might be more than 
one copy of particular miRNAs. The suggestion has been made that some miRNAs are also 
encoded in antisense DNA, which is not transcribed to the mRNA (Bartel, 2004).  
1.1.1 MicroRNA processing 
Regulation of miRNA expression depends on transcription factors and epigenetic 
mechanisms, such as DNA methylation and histone modification of the miRNA genomic 
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region. Over the course of their lifecycle, miRNAs must undergo extensive post-
transcriptional modifications. Genes encoding miRNAs are transcribed with RNA-
polymerase II or RNA-polymerase III (Pol II or Pol III) into a primary transcript, 200 
nucleotides (nt) to several kilobases (kb) long, known as a pri-miRNA. Mature miRNA 
sequences are usually localized to regions of imperfect stem-loop. The resulting pri-
miRNA (with poly-A tail and 7-methylguanosine cap) is processed by an RNase III 
enzyme called Drosha and a double-stranded RNA-binding protein, DGCR8 (DiGeorge 
syndrome critical region) in the cell nucleus, into a 70-nt stem-loop structure called a pre-
miRNA. The resulting stem-loop structure, with a monophosphate at the 5' terminus and a 
2-nt overhang with a hydroxyl group at the 3' terminus, is imported into the cytoplasm by 
a transporter protein, Exportin 5. After GTP hydrolysis, with consequent release of the 
pre-miRNA, the double-stranded RNA portion of pre-miRNA is bound and cleaved by 
Dicer (RNase III enzyme) together with co-factor TRBP (transactivating region binding 
protein). The action of these proteins removes the terminal loop and produces a 
miRNA:miRNA* duplex, which is a transient intermediate in miRNA biogenesis (20–25 
nt), with a 2-nt overhanging its 3' UTR. One of the two strands of each fragment, known 
as the guide strand (miRNA), together with proteins argonaute (Ago 1-4), helicases, 
nucleases and RNA binding proteins, is incorporated into a complex called the miRNA-
containing ribonucleoprotein complex (miRNP) or RNA-induced silencing complex 
(RISC). The resulting complex is responsible for base-pairing with complementary mRNA 
sequences. The other strand, miRNA* or passenger strand, is presumably degraded, 
although there are increasing prospects that either or both strands may be functional. It is 
believed that the guide strand is determined on the basis of the less energetically stable 5' 
end (Bartel, 2004; Pillai, 2005; Pillai et al., 2007; Ying et al., 2008). Intronic miRNAs bypass 
Drosha cleavage and rely on the action of the pre-mRNA splicing/debranching machinery 
to produce an approx. 60 nt precursor miRNA hairpin (pre-miRNA) (Kim & Kim, 2007). 
The miRNA processing is summarized in Figure 1. 
1.1.2 MicroRNAs mechanism  
The functional role of miRNA varies, depending on the organism, but the primary 
mechanism of miRNA action in mammals is to inhibit mRNA translation. The catalytic 
components of miRNP/RISC complex are Ago proteins. After base pairing between the 
miRNA and target mRNA, degradation of the target mRNA results when complementarity 
is perfect, or suppression of the translation occurs when base pairing between these two 
molecules is incomplete. Especially in animals, each miRNA can inhibit the translation of 
many different mRNAs (as many as 200 predicted target genes) without degrading the 
target mRNA. In addition, mRNA can be regulated by more than one miRNA. The 
cooperative action of multiple identical or different miRNP/RISCs appears to provide the 
most efficient translational inhibition. This explains the presence of multiple miRNA 
complementary sites in most genetically identified targets, and the cooperative action of 
miRNA:UTR interactions would provide an additional mechanism to increase the specificity 
of miRNAs. Proteins or mRNA secondary structures could restrict miRNP/RISC 
accessibility to the UTRs, or may facilitate recognition of the authentic mRNA targets 
(Bartel, 2004; Pillai, 2005; Pillai et al., 2007; Ying et al., 2008). It has been suggested that 
miRNAs may also be involved in regulation by binding to the 5' UTR of the target genes 
(Liu z. Et al, 2008). There is still the prospect that some miRNA might specify more than just 
post-transcriptional repression; some might in addition target DNA for transcriptional 
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silencing. Each of the examples (DNA methylation and silencing in plants, heterochromatin 
formation in fungi, DNA rearrangements in ciliates) suggests the existence of a nuclear 
RISC-like complex (Bartel, 2004). 
 
 
Legend: Pol II/PolIII, RNA-polymerase II and III; poly-A, poly-A tail; 7mGpppG, 7-methylguanosine 
cap; Drosha, RNase III enzyme; DGCR8, double stranded RNA-binding protein; Exportin 5,  transporter 
protein; Dicer, RNase III enzyme.   
Fig. 1. Schematic overview of the miRNA biogenesis pathway 
1.2 MicroRNA annotation in humans 
After the small isolated RNAs are annotated as miRNAs, based on expression and 
biogenesis criteria, they need to be named (Ambros et al., 2003; Berezikov et al., 2006). 
Perhaps the best examples of naming annotated miRNA in this context are those of muscle-
specific hsa-miR-133a-1, hsa-miR-133a-2 and hsa-miR-133b, and heart associated hsa-miR-199a-
3p and hsa-miR-199a-5p. The prefix hsa is designated for human miRNA (Homo sapiens), the 
term miR is designated for miRNA gene; the numbers 133 and 199 are unique identifying 
numbers that characterize the exact miRNA sequence; the letters a and b are used for 
paralogous miRNAs; numbers after the miRNA gene name, e.g., hsa-miR-133a numbers  
1 and 2, are used for one copy of genes encoded within the genome; 3p or 5p, in this case for 
hsa-miR-199a, is used when none of the miRNA duplex is degraded, or it has not yet been 
determined from which pre-miRNA arm the miRNA is degraded and from which pre-miRNA 
arm the miRNA is incorporated in the miRNP/RISC (Griffiths-Jones et al., 2008). 
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1.3 Target prediction and bioinformatics 
MicroRNAs are generally conserved in evolution, some quite broadly, others only in more 
closely related species (Bartel, 2004). Many computational methods have recently been 
developed for identifying potential miRNA targets (Ioshikes et al., 2007). Most of these 
methods search for multiple conserved regions of miRNA complementarities within 3' UTR; 
the most important parameters are therefore evolutionary conservation with regard to the 
quality and stability of base pairing. The interaction between seven consecutive nucleotides in 
the target mRNAs 3' UTR and the 2-8 nt (“seed sequence”) at the 5' miRNA end is believed to 
be important for base pairing. The majority of prediction programmes use pairing with the 
seed sequence as one of the major criteria. There are several available programs for predicting 
mRNA targets for specific miRNA or for predicting possible miRNA binding sites for specific 
mRNA, but none of these programs can be used as a means of independently validating the 
targets, and all predicted targets must be validated in vitro and in vivo (Kuhn et al., 2008). 
Further complicating target site prediction in mammals is the fact that not all 3' UTR sites with 
perfect complementarities to the miRNA seed nucleotides are functional. Moreover, mRNAs 
sites with imperfect seed complementarities can themselves be very good miRNA targets. In 
animals, there are far fewer mRNAs with near perfect complementarities to miRNAs. 
Bioinformatic analysis is therefore much noisier and more prone to false positives (Barnes et 
al., 2007). The most often used target prediction programs are perhaps TargetScan and PicTar, 
although others are often used, such as miRanda, microrna.org, miRBase etc. There is also a 
database available containing dysregulated miRNAs in different diseases or their profiling in 
various tissues (HMDD, Human MicroRNA Disease Database; Lu et al., 2008). Another useful 
database is Tarbase, in which all experimentally validated targets for all organisms and 
miRNAs are incorporated (Sethupathy et al., 2006).  
2. MicroRNA in regulating physiological functions 
Importance of miRNA processing pathway components. MicroRNAs and their associated 
proteins appear to be one of the more abundant ribonucleoprotein complexes within cells. 
Perhaps the best evidence of miRNAs being important for normal physiological functions is 
provided by experiments in which the components of the miRNA biogenesis pathway are 
depleted or over-expressed. Biochemical experiments in several eukaryotes have shown that 
DGCR8 is an essential co-factor of the RNAse II enzyme Drosha. In addition, the reduced 
enzymes Dicer and Drosha have been demonstrated in several diseases, as well as over-
expression of Dicer, Ago 2 and exportin-5 (Soifer et al., 2007).  
Outcomes of translational repression. By translational repression, miRNAs, in normal cell 
conditions can function in different ways. Firstly, for mRNAs that should not be expressed 
in a particular cell type, miRNAs reduce protein production to inconsequential levels 
(switch off the targets). Secondly, miRNAs can adjust protein output in a manner that allows 
for customized expression in different cell types but a more uniform level within each cell 
type (fine-tuning target expression). Thirdly, some miRNAs act as bystanders, for which 
down-regulation by miRNAs is tolerated or is negated by feedback processes (neutral target 
expression). MicroRNA functions have mainly been determined by in vivo experiments, by 
the phenotypic consequences of a mutated miRNA or an altered mRNA complementarity 
site, either of which can disrupt miRNA regulation. In some cases, function has been 
inferred from the effects of transgenic constructs that lead to ectopic expression of the 
miRNA (Bartel, 2004).  
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Physiological functions. Many miRNAs are expressed in a tissue-specific manner, e.g., miR-
208 is cardiac specific (van Rooij et al., 2007), miR-122 is liver specific (Girard et al., 2008), 
and/or cell-type specific manner (e.g. miR-223 is primarily expressed in granulocytes); they 
are important at distinct stages of development and have been found to regulate a variety of 
developmental and physiological processes (Williams, 2008). In terms of development, 
miRNAs are important in regulating morphogenesis and the maintenance of 
undifferentiated or incompletely differentiated cell types, such as stem cell differentiation, 
cardiac and skeletal muscle development, neurogenesis, hematopoiesis etc. Recently 
discovered miRNA functions include control of cell-fate decision, cell proliferation, cell 
death, neuronal patterning, modulation of hematopoietic lineage differentiation and 
controlling the timing of developmental transitions (Callis et al., 2007; Fazi & Nervi, 2008; Li 
& Gregory, 2008). In physiological conditions, miRNAs are involved in metabolism, 
regulation of insulin secretion, cholesterol metabolism, resistance to viral infection and 
oxidative stress, immune response etc (Lodish et al., 2007; Williams, 2008). With all different 
genes and expression patterns, it is reasonable to propose that every cell type at each 
developmental stage might have a distinct miRNA expression profile. MicroRNA biogenesis 
and activity is now regarded as a key regulatory mechanism in maintenance tissue identity 
during embryogenesis and adult life. 
3. MicroRNAs and disease 
Presence of SNPs. Disruption of miRNA target interaction in the form of single-nucleotide 
polymorphisms (SNPs), either in the miRNA gene or its target site (3′ UTR mRNA), can lead 
to complete gain or loss of the miRNA function and thus account for a diseased state (e.g.  
AT1R and miR-155, Martin et al., 2007). In contrast to the miRNA target sites in mRNA 
transcripts, in which the potential of variation is huge, variants identified in miRNA 
precursor sequences tend to be extremely rare, usually restricted to one individual. The 
presence of SNPs in pri-miRNA or pre-miRNA can also affect the processing of miRNAs and 
their expression, which can also result in different disease outcomes (Barnes et al., 2007).  
Aberrant expression of miRNAs. Recent advances in miRNA research have provided evidence 
of an miRNA association with various pathological conditions. These can be due to 
abnormal miRNA expression profiles, genomic rearrangements or epigenetic mechanisms 
activated in diseased human tissues. Aberrant miRNAs expression and processing is 
associated with genetic disorders, cancer, autoimmune and inflammatory diseases, and 
neurodegenerative and cardiovascular disorders (Perera & Ray, 2007). It is estimated that 50 
% of miRNA genes are located at fragile chromosome sites and associated with the 
development of cancer. MicroRNAs can in addition act as tumour suppressors or proto-
oncogens during the course of carcinogenesis (Cho, 2009).  
4. MicroRNAs in heart physiology and disease 
Cardiac specific Dicer deletion. One of the most important studies showing that miRNAs are 
important in heart physiology, as well as in heart disease, concerned the cardiac specific 
knockout of Dicer in prenatal mice. Dicer deletion resulted in rapidly progressive dilated 
cardiomyopathy, heart failure and postnatal mortality; early mortality was due to heart 
defects, such as pericardial edema and underdevelopment of the ventricular myocardium. 
Dicer mutant mice showed a severe decrease in heart contractile function, due to aberrant 
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expression and loss of cardiac contractile proteins, and profound sarcomere disarray, 
resulting in reduced heart rates. Decreased Dicer expression has consistently been detected 
in end-stage human cardiomyopathy and heart failure. In contrast, increased expression has 
been observed after left ventricular assist device support in humans, which is used to 
improve cardiac function (Chen et al., 2008). Furthermore, postnatal experiments of Dicer 
loss in cardiomyocytes of young mice resulted in sudden cardiac death, probably due to 
arrhythmias. Loss of Dicer in adult myocardium induces rapid and dramatic biventricular 
enlargement, accompanied by myocyte hypertrophy, myofiber disarray, ventricular fibrosis 
and strong induction of foetal gene transcripts (da Costa Martins et al, 2008). These results 
clearly demonstrated that components of miRNA processing are important for cardiac 
contractility, suggesting one of the crucial roles of miRNAs in normal and pathological 
functions of the heart. Changes in miRNA biogenesis affect both juvenile and adult 
myocardial morphology, suggesting a huge biological impact of miRNAs in the postnatal 
heart. It can therefore be concluded that Dicer down-regulation probably affects the 
expression of hundreds of miRNAs, which results in a severe disease outcome.  
Heart disease. MicroRNA research in cardiovascular diseases has only just started. There is 
growing evidence to suggest that miRNAs are involved in the regulation of developmental, 
physiologic and pathologic conditions of the heart. Cardiac diseases, including those with 
progressive degeneration, might involve abnormal miRNA regulation leading to loss of 
renewal of the cardiac muscle cells. The majority of studies have been concerned with 
development, conduct and pathology, focusing on hypertrophy, end-stage heart failure, 
cardiomyopathy and myocardial infarction (Schipper et al., 2008; Thum et al., 2007; Xiao et 
al., 2008; Yin et al, 2008). Stress, associated with cardiac diseases, contributes to miRNA 
expression patterns in the heart, suggesting that miRNAs might function in stress-related 
factors affecting cardiac structure and function. Previous studies of cardiac disease have 
focused on miRNAs that are primarily expressed in cardiomyocytes; however, there is 
mounting evidence that other miRNAs expressed in the human heart have an impact on 
cardiovascular disease (Cordes et al., 2009; Rane et al., 2009; Roy et al., 2009; Song et al., 
2010). In several studies, miRNA microarray analysis has been performed using cell lines 
and an animal model of hypertrophy (Cheng et al., 2007; Sayed et al., 2007; van Rooij et al., 
2006; Tatsuguchi et al., 2007; Thum et al., 2008), human cardiomyopathies and aortic 
stenosis (Ikeda et al., 2007; Sucharov et al., 2008), end-stage heart failure (Matkovich et al., 
2009; Thum et al., 2007), fibrosis (van Rooij et al., 2008), myocardial infarction (Roy et al., 
2009) and development (Niu et al., 2008) and animal model of remodelling and reverse 
remodelling of the heart (Wang et al., 2009) and all other forms of myocardial ischemia. 
Among the genes activated by oxidative stress are the transcription factors that orchestrate 
the expression of a wide variety of responses affecting metabolism, angiogenesis, cell 
survival and oxygen delivery and, in addition, miRNA expression, thought to be critical for 
adaptation to low oxygen. In response to low oxygen, a number of miRNAs are up- or 
down-regulated, with several of these dependent on hypoxia-inducible-factor, a 
transcription factor that plays essential role in the homeostatic response to hypoxia 
(Kulshreshtha et al., 2007; Kulshreshtha et al., 2008).  
Heart development. The heart is the first organ to form and to function during development. It 
has been established that miRNAs represent developmental expression patterns, important 
for timing developmental decisions and pattern formation (Morton et al., 2008). In addition, 
it has been shown that some miRNA patterns are similar in diseased and foetal hearts, 
supporting the concept of reactivation of the foetal gene program in cardiovascular diseases. 
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MicroRNA expression in failing hearts has an increased similarity to that of foetal cardiac 
tissue, suggesting that foetal gene expression in diseased hearts is a hallmark of cardiac 
stress (Thum et al., 2007).  
4.1 Cardiac and muscle specific microRNAs in heart 
MicroRNAs miR-1, miR-133, miR-206 and miR-208, are considered to be muscle and/or 
cardiac specific because they are preferentially but not exclusively expressed in muscle 
and/or cardiac tissue. Among mammalian miRNAs identified so far, miR-1 and miR-133 are 
believed to have a muscle specific expression pattern, with an impact on the regulation of 
heart development. Cardiac expression of miR-1 is controlled by SRF (serum response 
factor) and myocardin; similar to miR-1, miR-133 expression in the heart is controlled by SRF 
(Niu et al., 2008). Currently, a number of miRNAs have been described as enriched or 
muscle specific, but, to the best of our knowledge, only miR-208 has been described as 
cardiac specific. 
4.1.1 Cardiac specific miR-208  
As an identified cardiac specific miRNA, miR-208 is believed to play an important role in 
response to stress, such as pressure overload, activated calcineurin or hypothyroidism. 
MicroRNA miR-208 is encoded by an intron of Myh6, a gene encoding human and mouse ǂ-
cardiac muscle myosin heavy chain (┙MHC). By targeting THRAP1, a co-factor of the thyroid 
hormone nuclear receptor, it mediates down-regulation of ┙MHC and up-regulation of ǃ-
cardiac muscle myosin heavy chain (┚MHC) in mice, the primary contractile proteins of the 
heart. Changes in contractile proteins are accompanied by hypertrophy and fibrosis, 
resulting eventually in the diminution of contractility; these changes are also referred to as 
remodelling. Experimental models of miR-208 null animals (mice), which failed to undergo 
stress-induced remodelling and hypertrophic growth in response to activated calcineurin 
signalling or pressure-overload-induced stress, and failed to induce ┚MHC up-regulation in 
response to hypothyroidism, support the suggested role of miR-208 in remodelling (van 
Rooij et al, 2007). It was recently determined that this miR-208 gene corresponds to miR-208a 
and that it is a member of a family that also includes miR-208b, which is encoded within an 
intron of Myh7 (gene coding ßMHC). These two miRNAs (miR-208a and miR-208b) are 
differentially expressed in mice heart during development, paralleling the expression of 
their host genes (Callis et al., 2009).  
4.1.2 Muscle specific miR-1 and miR-133 
Development. Muscle miRNAs are mainly controlled by myogenic transcription factors; 
through cardiac development they fine-tune regulatory protein levels in a spatiotemporal 
manner. MicroRNAs miR-1 and miR-133 are clustered on the same chromosome loci (miR-1-
1 and miR-133a-2 on chromosome 20, and miR-1-2 and miR-133a-1 on chromosome 18) and 
are transcribed together in a tissue specific manner. Using cell culture and animal model 
experiments, it has recently been shown that miR-1 and miR-133 have opposite roles in 
muscle development, with miR-1 promoting myoblast differentiation and miR-133 
promoting myoblast proliferation; both miR-1 and miR-133 target SRF, with miR-1 also 
targeting transcription repressor, histone deacteylase HDAC4 thus promoting myogenesis 
(Chen et al., 2006; Niu et al., 2008). Over-expression of miR-1 in developing mouse hearts 
results in decreased cardiomyocyte proliferation and premature differentiation through 
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down-regulation of transcription factor Hand2. Target deletion of miR-1 causes death in utero 
of the majority of offspring, due to defects in cardiac morphogenesis. The surviving ones die 
later due to conductivity problems. It is suggested that a precise dosage of Hand2 is essential 
for normal cardiomyocyte development and morphogenesis (Zhao et al., 2005). Experiments 
using mouse models of an miR-1-2 null animal suggest that miR-1-2 has a non-redundant 
role with miR-1-1 in the heart, despite their apparent overlapping expression patterns. Half 
of the miR-1-2 null animals died, others suffered from incomplete ventricular septation, 
indicating abnormal cardiogenesis. It would be useful to know whether deletion of miR-1-1 
invokes a similar phenotype, and whether deletion of both copies causes a more severe 
phenotype (Zhao et al., 2007). Finally, it has been shown that, during development, miR-133 
regulates cardiogenesis by targeting nuclear factor Nelf-A/Whsc2 (Care et al., 2007).  
Apoptosis. Loss of cardiac muscle cells due to apoptotic cell death is a common process in 
heart development, as well as in myocardial ischemia, cardiac hypertrophy and heart 
failure. MicroRNAs are also implicated in cardiovascular disease as regulators of apoptosis. 
Opposite effects of miR-1 and miR-133 regulating cardiomyocyte apoptosis induced by 
oxidative stress have been described, with a pro-apoptotic role of miR-1 (targeting HSP60 
and HSP70, heat-shock proteins) and anti-apoptotic role of miR-133 (targeting caspase-9) (Xu 
et al., 2007).  
Hypertrophy. Both miR-1 and miR-133 have been demonstrated to be dysregulated in 
hypertrophic and failing hearts and in myocardial infarction in both animals and humans. 
MicroRNA miR-133 showed down-regulation in patients with hypertrophic 
cardiomyopathy and in mouse models of cardiac hypertrophy. The predicted targets for 
miR-133 are Rhoa, a GDP-GTP exchange protein regulating cardiac hypertrophy, and Cdc42, 
a signal transduction kinase implicated in hypertrophy; both miRNAs are involved in cell 
growth, myofibrillar rearrangements and regulation of contractility. Another target was 
determined, Nelf-A/Whsc2, a nuclear factor involved in cardiogenesis but the role of Nelf-
A/Whsc2 in cardiac hypertrophy has not yet been defined (Care et al., 2007). Although it is 
also believed that miR-1 expression is down-regulated during cardiac hypertrophy, results 
are somewhat controversial; additional genetic studies are therefore needed to demonstrate 
clearly a direct role of miR-1 in the regulation of cardiac hypertrophy. However, miR-1 
targets in the context of cell growth, contractility and extracellular matrix have been 
determined, including RasGAP, Cdk9, Rheb and fibronectin (Care et al., 2007). 
4.2 MicroRNAs controlling cardiac excitability 
The electrical-conduction system, which maintains proper heart rhythmicity, has been 
shown to be regulated by miRNAs that regulate the expression of its components and 
therefore possess the potential to induce arrhythmia. Dysregulated miRNA expression 
might affect the expression of ion channel genes, leading to arrhythmogenesis; it has been 
postulated that miRNAs control cardiac excitability through this regulation. Using 
bioinformatics and experimental approaches, a number of miRNAs have recently been 
proposed as having the potential to regulate human ion channel genes. The matrix of 
miRNAs that are expressed in cardiac myocytes has been established, with the potential to 
regulate genes encoding cardiac ion channels and transporters. The author proposed that 
multiple miRNAs might be critically involved in the electrical/ionic remodelling process in 
heart disease through altering the expression of the genes in cardiac myocytes (Luo et al., 
2010). MicroRNAs known up to date to target cardiac excitability are listet in Table 1 with 
corresponding target genes and their functions.  
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4.2.1 Cardiac specific miR-208 
As previously reported, the expression of miR-208a and miR-208b is not just 
developmentally regulated in the heart, but also pathologically. In a recent study, it was 
postulated that miR-208a expression was sufficient to induce arrhythmias; furthermore, 
experiments on genetic deletion of miR-208a in mice revealed that miR-208a is required for 
proper cardiac conduction and expression of the transcription factor GATA4 and gap 
junction protein connexin 40 (Cx 40). MicroRNA miR-208 is therefore required for 
maintaining the expression of cardiac transcription factors known to be important for the 
development of the conduction system. Over-expression of miR-208a results in cardiac 
conduction abnormalities and suggests that miR-208a regulates cardiac conduction system 
components. Studies on mice lacking miR-208a suggest that these mice suffer atrial 
fibrillation. Furthermore, Cx 40 expression is restricted to the atria, more precisely in the His 
bundle and Purkinje fibres. Consistent with the phenotype of mice lacking miR-208a, mice 
lacking Cx 40 also suffer from first-degree AV block. It can be concluded, therefore, that 
miR-208a gain- and lost-of-function are associated with arrhythmias (Callis et al., 2009). 
4.2.2. Muscle specific miR-1 and miR-133 
MicroRNAs miR-1 and miR-133. The slow delayed rectifier current Iks, is constituted of 
channel complex, which is formed from KCNQI and KCNEI. Their expression is regionally 
heterogeneous; it is also changed by the pathological state of the heart. It has been 
experimentally established that the two genes, KCNQI and KCNEI, are targets for miR-133 
and miR-1, respectively. It was shown that expressions of miR-1 and miR-133 in the heart are 
spatially heterogeneous and that this may contribute to regional differences in the 
distribution of KCNQI and KCNE1. To confirm the hypothesis, it was shown that KCNQI has 
the opposite patterns of transmural and apical-basal gradients to those of miR-133, whereas 
the characteristic regional distribution of miR-1 may be one of the causal factors for the 
converse transmural and apical-base gradients of KCNEI. Thus, in areas in which miR-1 and 
miR-133 are less abundant, Iks are more densely expressed (Luo et al., 2007). In one of the 
first studies of miRNA influence on the cardiac conduction system, it was suggested that 
down-regulation of miR-1 and miR-133 contributes to arrhythmogenesis in hypertrophic and 
failing hearts, and that miR-1 and miR-133 play an important role in determining cardiac 
automaticity, possibly by re-expression of the pacemaker channel genes HCN2 and HCN4. 
Both miRNAs are involved in hypertrophy, with miR-133 believed to be a negative regulator 
of hypertrophic growth of heart muscle. By undergoing a remodelling process and 
hypertrophic growth, the heart adapts to impaired cardiac function. The remodelling 
process in the heart also includes electrical remodelling, which increases the risk of 
arrhythmogenesis by re-expression of the pacemaker channel HCN genes 
(hyperpolarization–activated cyclic-nucleotide-gated channels). The HCN2 gene has been 
shown to be a target of miR-133. In addition, pacemaker channels HCN2 and HCN4 have 
both been shown to be targets for miR-1, so its down-regulation may also lead to re-
expression of these pacemaker channels in a diseased heart. To date, these two miRNAs 
have a postulated role in regulating automaticity in the functioning of the If current. This is a 
mixed Na+K+ inward current, which is activated by hyperpolarization and is the main 
current of pacemaker activity in the sinoatrial node. If may therefore be controlled by miR-1 
and miR-133 through the regulation of HCN density (Luo et al., 2008). 
MicroRNA miR-1. Up-regulation of miR-1 has been reported in patients with coronary artery 
disease and in animal models in the border zone of myocardial infarction. Over-expression 
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of miR-1 in the hearts of adult rats leads to widened QRS complex, indicative of 
intraventricule conduction delay and the development of severe cardiac arrhythmia. Target 
mRNAs for miR-1 have been predicted as ion channel genes GJA1, which encodes gap-
junction protein connexin 43, and KCNJ2, which encodes the K+ channel subunit Kir2.1. 
Knockdown of endogenous miR-1 can inhibit ischemic arrhythmias. Therefore, miR-1 might 
contribute to re-entry through decreased intracellular coupling via the repression of GJA1 
(Yang et al., 2007). In contrast to this research, it was shown that miR-1 levels are greatly 
reduced in the left atrium of patients with persistent atrial fibrillation (AF), possibly 
resulting in up-regulation of Kir2.1 subunits, which leads to increased Ik1. Up-regulation of 
this inward-rectifier current is important for AF maintenance (Girmatsion et al., 2009). A 
further miR-1 target involved in regulation of cardiac conductance is Irx5, a transcription 
factor that regulates cardiac repolarization by repressing Kcnd2. This gene encodes for 
potassium channel Kv4.2, which is responsible for transient outward K+ current. Normal 
expression of all three components, miR-1, Irx5 and Kcnd2, is required for maintaining the 
ventricular repolarisation gradient. Evidence was provided by deletion of the miR-1-2 gene, 
which resulted in the death of half of the mice at birth, and those surviving to adulthood 
showed an aberrant heart rate and repolarization (Zhao et al., 2007). Calcium channels 
account for excitation-contraction coupling and also contribute to pacemaker activities. The 
effect of increased expression of miR-1 on excitation-contraction coupling and Ca2+ cycling 
has been investigated in rat ventricular myocytes. It was shown that miR-1 over-expression 
increased phosphorylation of the ryanodine receptor (RyR2) by selective decrease in 
expression of protein phosphatase PP2A. RyR channels on the sarcoplasmic reticulum (SR) 
are essential for activation of contractile filaments during myocardial contraction; RyR2 is 
regulated by kinases and phosphathases, its activity depends on the phosphorylation state. 
Through translational inhibition, miR-1 causes hyperphosphorylation of RyR2 thus 
enhancing RyR2 activity and promoting arhythmogenic SR Ca2+ release. The author 
concluded that miR-1 enhances cardiac excitation-contraction coupling by selectively 
increasing phosphorylation of the L-type and RyR2 channels via disrupting localization of 
PP2A activity to these channels (Terenteyev et al., 2009).  
MicroRNA miR-133. In vitro studies have identified ERG (ether-a-go-go related gene) as an 
miR-133 target, K+ channel (IKr), in cardiomyocytes; its repression may contribute to 
depression and subsequent QT prolongation in diabetic hearts. ERG protein level was 
decreased in the ventricle of diabetic hearts; in contrast, increased expression of miR-133 and 
SRF was detected in the same diabetic subjects. Down-regulation of ERG is responsible for 
arrhythmias in diabetic hearts caused by QT prolongation (Xiao et al., 2006).  
4.2.3 Other miRNAs regulating cardiac excitability 
Another possible mechanism of miRNA regulating the L-type Ca2+ current, reduction of which 
is associated with atrial electrical remodelling and atrial fibrillation, has recently been 
suggested. In particular, miR-328 level was approx.  4-fold up-regulated, targeting the L-type 
Ca2+ channel genes, CACNA1C and CACNB1. The author therefore concluded that miR-328 
contributes to adverse atrial electric remodelling in AF and was postulated as a novel molecular 
mechanism for AF (Lu et al., 2010). Furthermore, it has been shown that nicotine-induced atrial 
remodelling, which represents an increased risk for atrial fibrillation, results in significant up-
regulation of TGF-ß1 and TGF-ßRII and, remarkably, a decrease in the levels of miR-133 and miR-
590, which at least partly accounts for TGF-ß1 and TGF-ßRII up-regulation. It is suggested that 
the antifibrotic effect of both miR-133 and miR-590 are implicated in AF (Shan et al., 2009). 
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miRNA 
Target 
gene 
Target gene description Regulating process Reference 
miR-1 Hand2 
transcription factor, 
heart- and neural crest 
derivatives-expressed 
protein 2 
developing 
ventricular 
chambers, cardiac 
morphogenesis 
Zhao et al., 
2005 
 Irx5 iroquois homeobox 5 
pattern formation of 
vertebrate embryos, 
heart development 
Zhao et al., 
2007 
 GJA1 
gap junction protein, 
alpha 1, connexin 43 conduction between 
cells and within a 
cell 
Yang et al., 
2007 
 KCNJ2 
potassium inwardly-
rectifying channel, 
subfamily J, member 2 
 KCNEI 
potassium voltage-gated 
channel, Iks-related 
family, member 1 
regional 
heterogeneity of 
expression 
Luo et al., 
2007 
 
HCN2, 
HCN4 
hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 
pacemaker channels 
Luo et al., 
2007 
 PP2A protein phosphatase 2A 
regulating RyR2 
phosphorylation 
Terenteyev 
et al., 2009 
miR-133 ERG ether-a-go-go-like gene 
long QT sindrom, 
diabetes mellitus 
Xiao et al., 
2007 
 KCNQI 
potassium voltage-gated 
channel, KQT-like 
subfamily, member 1 
regional 
heterogeneity of 
expression 
Luo et al., 
2007 
 HCN2 
hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 2 
pacemaker channels 
Luo et al., 
2007 
 
TGFB1, 
TGFBRII 
transforming growth 
factor, beta 1 and its 
receptor 
nicotin-induced 
atrial remodelling 
Shan et al., 
2009 
miR-208 
GATA4, 
Cx 40 
GATA binding protein 4 
and connexin 40 
heart conduction 
and arrhythmia 
Callis et al., 
2009 
miR-590 
TGFB1, 
TGFBRII 
transforming growth 
factor, beta 1 and its 
receptor 
nicotin-induced 
atrial remodelling 
Shan et al., 
2009 
miR-328 
CACNA1/ 
CACNB1 
voltage-dependent 
calcium channel 
calcium transport 
Lu et al., 
2010 
Table 1. MicroRNAs regulating cardiac excitation, its target genes and function. 
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5. Therapeutic potentials of microRNAs 
MicroRNA expression patterns are dynamically regulated during various diseases, thus 
providing an opportunity to use them as biomarkers or diagnosis indicators and for 
prognosis. MicroRNAs are small molecules, making their in vivo delivery feasible. The use 
of chemically modified oligonucleotides either to target a specific miRNA or disrupt 
miRNA-mRNA binding may lead to inactivation of pathological miRNA. MicroRNAs may 
therefore serve as therapeutic targets in the future (Liu Z. et al, 2008; Soifer et al., 2008).  
5.1 Replenishing small RNAs  
For an miRNA that is under-expressed, re-introduction of the mature miRNA into the 
affected tissue would restore regulation of the target gene. For this purpose, artificial 
miRNA have been developed (miRNA mimic) to enhance the expression of beneficial 
miRNAs or the introduction of short hairpin duplex, similar to pre-miRNA, into the cell. 
These findings raise the hope that re-introduction of certain miRNAs (e.g., miR-1, miR-133 or 
miR-208), depending on the disease outcome, might reduce life threatening arrhythmias, a 
frequent cause of death in patients with cardiovascular disease, or heart remodelling 
associated with prolonged ischemia, which often results in end-stage heart failure and poor 
prognosis (Liu Z. et al, 2008; Soifer et al., 2008). In vivo over-expression of miR-133 protected 
animals from agonist induced cardiac hypertrophy, whereas reduction in wild-type mice 
(anti-miRNA antisense antagomir molecules secreted by implanted osmotic pumps) caused 
an increase in hypertrophic markers. This suggests that individual miRNAs are potential 
therapeutic agents, provided that their expression or delivery can be targeted to appropriate 
tissue. However, care should be taken, since over-production of miR-133 induces 
arrhythmias (Care et al., 2007). Most of the developed protocols have used local 
administration in easily accessible tissue; systemic delivery has also some promising results; 
the major challenge remains tissue and cell-type specific targeting (Liu Z. et al, 2008; Soifer 
et al., 2008). 
5.2 Inhibiting small RNAs  
ASOs are short and single-stranded antisense oligonucleotides and, in the context of miRNA 
inhibition, are called AMOs, anti-miRNA oligonucleotides. Over-expressed miRNA can be 
down-regulated by reducing the mature miRNA level through direct targeting (mature 
miRNA, pri-miRNA or pre-miRNA) or by reducing the components of miRNA biogenesis. 
Chemically engineered oligonucleotides, termed “antagomirs”, have been developed and 
proven to be efficient and specific silencers of endogenous miRNAs in mice. Chemical 
modifications and cholesterol conjugations stabilize and facilitate intravenous delivery of 
antagomirs. They interact with miRNAs in the cytoplasm and lead to specific miRNA down-
regulation when injected systemically or locally (Liu Z. et al, 2008; Soifer et al., 2008). Direct 
injection of lipid-complexed antagomir oligonucleotides against miR-1 into rat hearts 
protected the animals from induced arrhythmias, suggesting that transient down-regulation 
of miR-1 could provide therapeutic benefits to those suffering from acute myocardial 
infarctions (Yang et al., 2007). In another approach, miRNA sponges have been developed to 
inhibit several miRNAs; miRNA sponges possess multiple binding sites and could be useful 
for sequestering an miRNA family. Furthermore, miR-masks and miR-erasers have also 
been developed; an miR-mask has been designed for masking the miRNA binding site on 
target mRNA, whereas an miR-eraser is similar to miR-sponges, except that the miR-eraser 
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uses only two copies of the antisense sequence. Gene-specific miRNA mimic and miRNA-
masking antisense approaches have been used to test the possibility of using miRNAs and 
their corresponding targets as therapeutic targets. The expression of the cardiac pacemaker 
channel genes, HCN2 and HCN4, has been manipulated via the mentioned approaches. 
MicroRNA mimics repressed protein levels, whereas miRNA masking markedly enhanced 
HCN2/HCN4 expression and function (Xiao et al., 2007). In a recent study, the authors 
proposed that arhhythomgenesis after intracardiac skeletal myoblast (SKM) transplantation, 
a promising therapy for myocardial infarct repair, may be related to the differentiation state 
of (SKM). It was shown that miR-181a plays an important role in myobast differentiation, so 
using lentivirus mediated oligonucleotides against miR-181a, the authors demonstrated 
reduced arrhythmias post SKM transplantation (Li et al., 2009).   
We need more knowledge concerning which miRNAs to target, how to produce and stabilize 
them, how to direct them to the heart and not systemically. The specificity of drug-like 
oligonucleotides is important, because of the off-target effect. The off-target effect is also a 
significant challenge, especially considering that miRNA-mediated repression often requires a 
homology of only six to seven nucleotides in the seed region of the miRNA and mRNA target 
site. Toxicity due to chemical modifications, which is used to facilitate cellular uptake and 
prevent degradation, should be take into account (Liu Z. et al, 2008; Soifer et al., 2008).  
6. Conclusions 
The field of miRNA is largely undiscovered territory, a young, emerging field of research, 
and we are just beginning to understand the role of miRNAs in the cardiovascular context. 
Recent advances in the research of miRNAs suggest that miRNAs modulate a wide variety 
of cardiac functions with developmental, (patho)physiological and clinical implications. The 
miRNA level in the myocardium must be kept within a proper concentration range to 
maintain normal cardiac conduction; excessive either decrease or increase in the level of 
some miRNAs can induce arrhythmia, which supports the central role of some miRNAs in 
fine-tuning the regulation of cardiac electrophysiology in pathological and normal 
conditions. The role of miRNAs in the pathogenesis of the heart and vessels points to the 
possibility of miRNA targets for the treatment of cardiovascular disease in previously 
unconsidered medical therapies. 
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